S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma.

Kin-Hoe Chow, The Jackson Laboratory
Hee Jung Park
Joshy George, The Jackson Laboratory
Keiko Yamamoto
Andrew D Gallup
Joel H. Graber, The Jackson Laboratory
Yuanxin Chen
Wen Jiang
Dennis Steindler
Eric G Neilson
Betty Y S Kim
Kyuson Yun


Glioma stem cells (GSCs) and epithelial-mesenchymal transition (EMT) are strongly associated with therapy resistance and tumor recurrence, but the underlying mechanisms are incompletely understood. Here we show that S100A4 is a novel biomarker of GSCs. S100A4+ cells in gliomas are enriched with cancer cells that have tumor-initiating and sphere-forming abilities, with the majority located in perivascular niches where GSCs are found. Selective ablation of S100A4-expressing cells was sufficient to block tumor growth in vitro and in vivo. We also identified S100A4 as a critical regulator of GSC self-renewal in mouse and patient-derived glioma tumorspheres. In contrast to previous reports of S100A4 as a reporter of EMT, we discovered that S100A4 is an upstream regulator of the master EMT regulators SNAIL2 and ZEB along with other mesenchymal transition regulators in glioblastoma. Overall, our results establish S100A4 as a central node in a molecular network that controls stemness and EMT in glioblastoma, suggesting S100A4 as a candidate therapeutic target. Cancer Res 2017 Aug 14 [Epub ahead of print]